Hepatitis B vaccination coverage among Iranian children aged 15-26 months in 2006 by Esteghamati, A. et al.
طسوتلما قشرل ةيحصلا ةلجلماشرع عباسلا دلجلما 
نياثلا ددعلا
93
Hepatitis B vaccination coverage among Iranian 
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ABSTRACT  This study in 2006 estimated the hepatitis B virus (HBV) vaccination coverage in the Islamic Republic 
of Iran at the national and district levels in urban, rural and remote populations of 41 university health service 
areas. Of 21 905 children recruited to the study, vaccination coverage based on vaccination card records was 
100% in 14, 15 and 10 of the 41 university areas for the 1st, 2nd and 3rd doses of HBV respectively. National levels 
of HBV1, HBV2 and HBV3 coverage were 98.9%, 98.8% and 98.4% respectively. The lowest HBV vaccination 
coverage rate was 90.7% (in a remote district). HBV vaccination coverage was at an acceptable level in Iranian 
children.
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2006 ماع في ًارهش 26 و 15 ينب ام مهرماعأ حوارـتت نيذلا ينيناريلإا لافطلأا ينب »بي« يدبكلا باهتللاا حاقلب ةيطغتلا
ينيقي ةمطاف ،لدنشور اضرملاغ ،ليمآ رلااس دوعسم ،ايوك يدهم دممح ،يفجن لييل ،راكتشك ليعسابع ،يتماقتسا اضرلا دبع
 قطانلما ىوتسمو ينطولا ىوتسلما لىع ةيملاسلإا ناريإ ةيروهجم في »بي« يدبكلا باهتللاا حاقلب ةيطغتلا ريدقتب 2006 ماع في نوثحابلا ماق :ةصلالخا
 نمو .ةعماج ينعبرأو ىدحلإ ةعباتلا ةيحصلا تامدلخا ميدقت عقاوم في كلذو ،ةيئانلا قطانلماو ةيفيرلاو ةيضرلحا قطانلما في يننطاقلا ناكسلا ينب
 ةعبات ةقطنم 41 لياجمإ نم 10و ،15و ،14 في %100 ميعطتلا ليجست ةقاطبل اقفو حاقللاب ةيطغتلا ةبسن تغلب ،ةساردلا مهتلمش ًلافط 21.905 لياجمإ
 لىولأا تاعرلجاب ةيطغتلل ةينطولا تلادعلما تناكو .لياوتلا لىع »بي« يدبكلا باهتللاا حاقل نم ةثلاثلاو ةيناثلاو لىولأا ةعرلجاب كلذو ،تاعماجلل
 قطانلما ىدحإ في( %90.7 تناكف حاقللاب ةيطغتلا في اضافخنا تلادعلما رثكأ امأ .لياوتلا لىع %98.4 و ،%98.8 و ،%98.9 حاقللا نم ةثلاثلاو ةيناثلاو
 .ةلوبقم ةيطغت ينيناريلإا لافطلأا ينب »بي« يدبكلا باهتللاا حاقلب ةيطغتلا َربَرتْعُت َّمث نمو .)ةيئانلا
Couverture vaccinale contre l’hépatite B des enfants iraniens âgés de 15 à 26 mois en 2006
RÉSUMÉ La présente étude, réalisée en 2006 en République islamique d’Iran, a estimé la couverture vaccinale 
contre le virus de l’hépatite B, à l’échelle du pays et des districts, des populations urbaines, rurales et isolées de 
41 zones de services de santé universitaires. Sur 21 905 enfants recrutés pour l’étude, la couverture vaccinale était 
de 100 % dans 14, 15 et 10 des 41 zones universitaires pour les première, deuxième et troisième doses du vaccin 
contre le virus de l’hépatite B, respectivement, selon les informations portées sur les cartes de vaccination. à 
l’échelle nationale, la couverture vaccinale était de 98,9 % pour la première dose, de 98,8 % pour la deuxième 
dose et de 98,4 % pour la troisième dose. Le taux de couverture vaccinale contre le virus de l’hépatite B le plus 
faible était de 90,7 % (dans un district éloigné). La couverture vaccinale contre le virus de l’hépatite B avait donc 
atteint un niveau acceptable chez les enfants iraniens.





global  health problem. There  are  ap-
proximately 350 million chronic hepa-
titis B surface antigen (HBsAg) carriers 












ity. All of  these countries  reach a  large 
proportion  of  their  population  with 
HBV  vaccination, which  is  reducing 
the  infection  rate, particularly  in Saudi 
Arabia [3]. 
The prevalence of HBsAg  among 
Iranian  voluntary  blood  donors  has 
decreased  from 1.8%  in 1998  to 0.4% 
in 2007  [4]. These carriers  constitute 
a major health problem  in  the  Islamic 
Republic of  Iran.  In  the absence of an 
effective  therapy, universal  immuniza-





in 1993  [5].  In practice, however,  the 
EPI may  be  affected  by  factors  such 
as  changes  in government and public 
health priorities. Regular monitoring 
and  periodical  evaluation  is  the  best 
way  to  assess  the  completeness  and 
effectiveness of HBV vaccination. For 
































3  sub-districts  were  defined  accord-




of  remote  districts was  very  small  in 
some university areas and there were no 
remote populations  in other districts; 
therefore,  we  used  finite  population 
correction  to  calculate  the  corrected 
sample size in these populations. 
Using cluster  sampling [6], we de-
fined 30  clusters  of  7  participants  in 
each  in  the 3  sub-districts of  the uni-
versity health  service  areas. To  iden-
tify clusters, we obtained  the  list of  all 
households in each population (urban, 
rural  and  remote)  from  the deputy of 
health  in all 41 university  areas based 
on  the  last  health  census  [Deputy of 
Health, Ministry of Health and Medical 
Education, unpublished report, Health 
Census  Report,  2005].  To  find  the 
first household of each cluster we used 
systematic  random  sampling  from  a 






fied by  randomly  selecting  a number 
between 1 and ≤ sampling interval. The 
first  household of  the  second  cluster 
was  located  by  adding  the  sampling 
interval  to  the  random number.  For 
subsequent  clusters, we  identified  the 
first household by adding the sampling 
interval  to  the  running  total. The right 
side neighbour (clockwise direction) of 
the first household  in each cluster was 





























card  is  completed  for  each  child  and 
all EPI vaccines (types and dates) are 
documented on  the  card. The card  is 
kept by  the child’s mother. Retention 
rates  of  the  immunization  card were 
noted as  the percentage of  individuals 
with a card at the time of the survey.


























used  to  consider  the design  effect  in 








age  in  each university  area  and at  the 
national level.
Results
We  recruited 21 905  children  to  the 
study. The mean age was 20.6 [standard 
deviation  (SD) 3.5] months  and  the 
male  to  female  ratio was 1:1.09. The 
proportions of urban, rural and remote 
sample  sizes were  41.5%,  39.5%  and 









centage coverage  in  the 3  sub-districts 
in  each university health  service  area 







age  of HBV1  in  14  of  41  university 
health  service  areas  was  100%.  Fars 
and Sabzevar had  the  lowest coverage 
(around 96%). Remote districts of Ilam 









service  areas  was  100%.  Fars  and 
Sabzevar  had  the  lowest  coverage, 
around 96% (Table 2). Among the sub-
districts,  the  vaccination  coverage  in 
remote districts of  Ilam and Kerman 













coverage  in  16  university  areas  was 
100% and the national level was 99.6%. 
Discussion















Islamic Republic of  Iran.  Some  local 
surveys  in  different  provinces  of  the 
country have been carried out with dif-
ferent methodologies and  samples.  In 
Kerman  province  (south-east  of  the 


























The coverage  rate of  the 3  recom-
mended doses (HBV1, HBV2, HBV3) 






ing  to data  from  the United Nations 
Children’s Fund (UNICEF), the rate of 
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Table 1 Record-based coverage of 1st dose of hepatitis B virus vaccine (HBV1) in Iranian children by university health service 
areas and sub-districts
University area Urban Rural Remote All districtsb
No. % No. % No. % No. %
Eastern Azerbaijan 209 100.0 207 100.0 213 100.0 629 100.0
Western Azerbaijan 210 98.1 211 100.0 208 99.5 629 99.0
Ardabil 214 97.2 207 100.0 209 100.0 630 98.4
Isfahan 210 100.0 210 99.5 57 100.0 477 99.9
Ilam 205 100.0 212 100.0 102 93.1 519 99.8
Babol 213 100.0 204 99.5 113 100.0 530 99.8
Booshehr 206 100.0 217 100.0 68 100.0 491 100.0
Tehran (TUMS)a 210 96.7 205 99.5 64 100.0 479 97.0
Tehran (IUMS)a 623 97.0 378 99.7 41 100.0 1042 97.1
Tehran (SBUMS)a 217 96.8 201 99.0 64 100.0 482 96.9
Jahrom 210 100.0 210 100.0 35 100.0 455 100.0
Chahar Mahal Bakhtyaree 210 100.0 210 100.0 0 0 420 100.0
Southern Khorasan 210 96.7 210 99.5 209 96.7 629 98.0
Khorasan Razavi 212 99.5 211 100.0 207 99.5 630 99.7
Northern Khorasan 231 97.0 182 100.0 217 99.5 630 98.5
Khoozestan 210 99.5 211 100.0 210 99.5 631 99.7
Rafsanjan 210 100.0 211 100.0 0 0 421 100.0
Zabol 217 93.1 203 100.0 21 100.0 441 97.5
Zanjan 210 100.0 200 98.5 133 100.0 543 99.3
Sabzevar 210 92.9 210 100.0 105 99.1 525 96.1
Semnan 210 99.5 210 100.0 33 100.0 453 99.6
Sistan–Baluchestan 203 97.0 200 99.5 227 99.1 630 98.3
Shahrood 217 100.0 210 100.0 16 100.0 443 100.0
Fars 210 95.7 209 97.6 212 99.5 631 96.3
Fasa 209 100.0 194 100.0 16 100.0 419 100.0
Qazvin 210 99.5 210 100.0 210 100.0 630 99.7
Qom 210 97.1 207 100.0 – – 417 97.2
Kashan 231 99.1 126 100.0 – – 357 99.2
Kordestan 210 100.0 209 100.0 57 100.0 476 100.0
Kerman 210 99.1 223 100.0 195 95.9 628 99.0
Kermanshah 210 100.0 210 99.1 112 99.1 532 99.7
Kohgelooye 209 100.0 210 100.0 20 100.0 439 100.0
Golestan 210 96.7 210 99.5 117 100.0 537 98.3
Gonabad 203 100.0 218 100.0 31 100.0 452 100.0
Gilan 209 100.0 210 99.5 125 99.2 544 99.8
Lorestan 217 100.0 209 100.0 202 100.0 628 100.0
Mazandaran 210 99.5 224 100.0 91 100.0 525 99.7
Markazi 209 100.0 210 100.0 – – 419 100.0
Hormozgan 210 100.0 232 100.0 188 100.0 630 100.0
Hamedan 210 100.0 210 100.0 42 100.0 462 100.0
Yazd 210 98.6 210 100.0 – – 420 98.8
Totalb – – – – – – – 98.9
aTehran province population was divided by 3 areas covered by Tehran University of Medical Sciences (TUMS), Iran University of Medical Sciences (IUMS) and Shahid 
Beheshti University of Medical Sciences (SBUMS). 
bWeighted proportions.  
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Table 2 Record-based coverage of 2nd dose of hepatitis B virus vaccine (HBV2) in Iranian children by university health 
service areas and sub-districts 
University area Urban Rural Remote All districtsb
No. % No. % No. % No. %
Azerbaijan Eastern 210 100.0 207 100.0 213 100.0 630 100.0
Azerbaijan Western 210 98.1 211 100.0 209 99.5 630 99.0
Ardabil 214 97.2 207 100.0 209 100.0 630 98.4
Isfahan 210 100.0 210 99.5 57 100.0 477 99.9
Ilam 205 100.0 212 100.0 102 93.1 519 99.8
Babol 213 100.0 205 100.0 113 100.0 531 100.0
Booshehr 206 100.0 217 100.0 68 100.0 491 100.0
Tehran (TUMS)a 210 96.7 205 99.5 64 100.0 479 97.0
Tehran (IUMS)a 626 96.7 379 99.7 42 100.0 1047 96.9
Tehran (SBUMS)a 217 97.2 201 99.0 64 100.0 482 97.3
Jahrom 210 100.0 210 100.0 35 100.0 455 100.0
Chahar Mahal Bakhtyaree 210 100.0 210 100.0 0 0 420 100.0
Khorasan Southern 210 97.1 210 99.5 209 96.7 629 98.2
Khorasan Razavi 212 99.1 211 100.0 207 99.5 630 99.3
Khorasan Northern 231 97.4 182 100.0 217 99.5 630 98.7
Khoozestan 210 99.5 211 100.0 210 99.5 631 99.7
Rafsanjan 210 99.5 211 100.0 – – 421 99.7
Zabol 217 93.1 203 100.0 21 100.0 441 97.5
Zanjan 210 100.0 200 100.0 133 100.0 543 100.0
Sabzevar 210 92.4 210 100.0 105 97.1 525 95.8
Semnan 210 99.5 210 100.0 33 100.0 453 99.6
Sistan–Baluchestan 203 96.6 200 99.0 227 99.6 630 98.0
Shahrood 217 100.0 210 100.0 16 100.0 443 100.0
Fars 210 95.7 209 97.6 212 99.5 631 96.3
Fasa 209 100.0 194 100.0 16 100.0 419 100.0
Qazvin 210 100.0 210 100.0 210 100.0 630 100.0
Qom 210 97.1 210 100.0 – – 420 97.2
Kashan 231 99.1 126 100.0 – – 357 99.2
Kordestan 210 100.0 209 100.0 57 100.0 476 100.0
Kerman 210 99.1 223 100.0 195 94.9 628 98.9
Kermanshah 210 100.0 208 99.0 112 96.4 530 99.7
Kohgelooye 209 100.0 210 100.0 20 100.0 439 100.0
Golestan 209 96.7 210 99.5 117 100.0 536 98.3
Gonabad 203 99.5 218 100.0 31 100.0 452 99.7
Gilan 209 98.6 210 99.5 125 99.2 544 99.0
Lorestan 217 100.0 210 100.0 202 100.0 629 100.0
Mazandaran 210 100.0 224 100.0 91 100.0 525 100.0
Markazi 209 100.0 210 100.0 – – 419 100.0
Hormozgan 210 100.0 232 100.0 188 99.5 630 99.9
Hamedan 210 100.0 210 100.0 42 100.0 462 100.0
Yazd 210 98.6 210 100.0 – – 420 98.8
Totalb – – – – – – – 98.8
aTehran province population was divided by 3 areas covered by Tehran University of Medical Sciences (TUMS), Iran University of Medical Sciences (IUMS) and Shahid 
Beheshti University of Medical Sciences (SBUMS). 
bWeighted proportions.  
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Table 3 Record-based coverage of 3rd dose of hepatitis B virus vaccine (HBV3) in Iranian children by university health service 
areas and sub-districts
University  area Urban Rural Remote All districtsb
No. % No. % No. % No. %
Eastern Azerbaijan 210 99.5 207 100.0 213 99.5 630 99.7
Western Azerbaijan 210 96.7 211 100.0 208 99.5 629 98.2
Ardabil 214 96.7 207 99.5 209 99.0 630 97.9
Isfahan 210 100.0 210 99.5 57 100.0 477 99.9
Ilam 205 100.0 212 99.1 102 91.2 519 99.3
Babol 213 100.0 205 100.0 113 100.0 531 100.0
Booshehr 206 100.0 217 100.0 68 100.0 491 100.0
Tehran (TUMS)a 210 96.7 205 99.0 64 100.0 479 97.0
Tehran (IUMS)a 625 96.3 379 99.5 42 100.0 1046 96.5
Tehran (SBUMS)a 217 96.8 201 98.5 64 100.0 482 96.8
Jahrom 210 99.5 210 100.0 35 97.1 455 99.7
Chahar Mahal Bakhtyaree 210 100.0 210 100.0 – – 420 100.0
Southern Khorasan 210 95.2 210 97.6 209 94.3 629 96.2
Khorasan Razavi 211 99.1 211 98.6 207 99.0 629 98.9
Northern Khorasan 231 96.1 182 100.0 216 99.5 629 98.1
Khoozestan 210 98.1 211 99.5 210 99.1 631 98.6
Rafsanjan 210 100.0 211 100.0 – – 421 100.0
Zabol 217 92.6 203 99.0 21 100.0 441 96.7
Zanjan 210 99.5 199 100.0 133 100.0 542 99.8
Sabzevar 210 91.4 210 100.0 105 98.1 525 95.3
Semnan 210 99.5 210 100.0 33 97.0 453 99.6
Sistan–Baluchestan 203 95.1 200 99.5 227 100.0 630 97.5
Shahrood 217 100.0 210 100.0 16 100.0 443 100.0
Fars 210 95.2 209 96.7 212 97.2 631 95.6
Fasa 209 100.0 194 100.0 16 100.0 419 100.0
Qazvin 210 100.0 210 100.0 210 100.0 630 100.0
Qom 210 96.7 210 100.0 – – 420 96.8
Kashan 231 99.1 126 100.0 – – 357 99.2
Kordestan 210 99.5 209 99.0 57 100.0 476 99.3
Kerman 210 98.6 223 97.3 194 90.7 627 97.3
Kermanshah 209 99.5 210 99.1 112 92.9 531 99.3
Kohgelooye 209 99.5 210 100.0 20 100.0 439 99.8
Golestan 210 96.7 210 99.5 117 99.1 537 98.3
Gonabad 203 99.5 218 100.0 31 100.0 452 99.7
Gilan 209 98.6 210 99.5 125 98.4 544 99.0
Lorestan 217 100.0 210 100.0 202 100.0 629 100.0
Mazandaran 210 100.0 224 99.6 91 100.0 525 99.8
Markazi 209 100.0 210 100.0 0 0 419 100.0
Hormozgan 210 96.7 232 97.8 188 92.0 630 96.7
Hamedan 210 100.0 210 100.0 42 100.0 462 100.0
Yazd 210 98.6 210 100.0 0 0 420 98.8
Totalb – – – – – – – 98.4
aTehran province population was divided by 3 areas covered by Tehran University of Medical Sciences (TUMS), Iran University of Medical Sciences (IUMS) and Shahid 
Beheshti University of Medical Sciences (SBUMS). 
bWeighted proportions.  








than  in Turkey  as  a whole  [15]. The 



















data  for  Italy  showed  that  the  rate of 
HBV vaccination was 95% [14] and in 
another study in Italy, coverage was 90% 
on average  [22].  In  the United States 

















in  Islamic Republic of  Iran  is a cost-ef-
fective strategy [27,28]. Administration 
of HBV vaccine at the time of marriage 
prevents  the  transmission of HBV  in 




and  reliable  source  for  assessing  vac-
cine coverage. Fortunately, more  than 
95% Iranian children had an  immuni-









HBV vaccination  coverage was  at  an 






vaccine  immunogenicity  especially  in 
high-risk areas.
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 Good health is essential to human welfare and to sustained economic and social development. WHO’s Member States 
have set themselves the target of developing their health financing systems to ensure that all people can use health 
services, while being protected against financial hardship associated with paying for them. 
In this report, the World Health Organization maps out what countries can do to modify their financing systems so 
they can move more quickly towards this goal - universal coverage - and sustain the gains that have been achieved. The 
report builds on new research and lessons learnt from country experience. It provides an action agenda for countries at 
all stages of development and proposes ways that the international community can better support efforts in low income 
countries to achieve universal coverage and improve health outcomes.
The report is available in Arabic, Chinese, English, French, Russian, Spanish, Portuguese, and the executive summary in 
German. The full report or individual chapters can be downloaded from:  
http://www.who.int/whr/2010/en/index.html
